The company has signed a long-term rental contract for a suitable building in Wilmington to produce the radioisotope yttrium-90 (Y-90), which is used in oncological applications for the treatment of liver cancer.
The decision to open a U.S. facility was prompted by the announcement last year that a Y-90 manufacturer was closing its U.S. operations.
Eckert & Ziegler last year had agreed to bring its Y-90 production technology to a partner in Chengdu, China, which would in return give Eckert & Ziegler long-term, exclusive global marketing and sales rights. Once the Boston plant is operational, the company expects to offer local supply of Y-90 to pharmaceutical companies or hospitals in all regions of the world.
Copyright © 2020 AuntMinnie.com